Valley National Advisers’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-157
| Closed | -$6K | – | 743 |
|
|
2024
Q2 | $6K | Hold |
157
| – | – | ﹤0.01% | 708 |
|
|
2024
Q1 | $4K | Hold |
157
| – | – | ﹤0.01% | 803 |
|
|
2023
Q4 | $3K | Hold |
157
| – | – | ﹤0.01% | 852 |
|
|
2023
Q3 | $4K | Hold |
157
| – | – | ﹤0.01% | 719 |
|
|
2023
Q2 | $5K | Hold |
157
| – | – | ﹤0.01% | 672 |
|
|
2023
Q1 | $4K | Hold |
157
| – | – | ﹤0.01% | 685 |
|
|
2022
Q4 | $4K | Hold |
157
| – | – | ﹤0.01% | 678 |
|
|
2022
Q3 | $4K | Hold |
157
| – | – | ﹤0.01% | 694 |
|
|
2022
Q2 | $4K | Hold |
157
| – | – | ﹤0.01% | 678 |
|
|
2022
Q1 | $5K | Hold |
157
| – | – | ﹤0.01% | 685 |
|
|
2021
Q4 | $5K | Hold |
157
| – | – | ﹤0.01% | 675 |
|
|
2021
Q3 | $7K | Hold |
157
| – | – | ﹤0.01% | 615 |
|
|
2021
Q2 | $9K | Hold |
157
| – | – | ﹤0.01% | 593 |
|
|
2021
Q1 | $8K | Hold |
157
| – | – | ﹤0.01% | 563 |
|
|
2020
Q4 | $7K | Hold |
157
| – | – | ﹤0.01% | 560 |
|
|
2020
Q3 | $5K | Hold |
157
| – | – | ﹤0.01% | 555 |
|
|
2020
Q2 | $8K | Hold |
157
| – | – | ﹤0.01% | 494 |
|
|
2020
Q1 | $6K | Hold |
157
| – | – | ﹤0.01% | 519 |
|
|
2019
Q4 | $7K | Hold |
157
| – | – | ﹤0.01% | 561 |
|
|
2019
Q3 | $5K | Hold |
157
| – | – | ﹤0.01% | 580 |
|
|
2019
Q2 | $8K | Hold |
157
| – | – | ﹤0.01% | 496 |
|
|
2019
Q1 | $11K | Hold |
157
| – | – | ﹤0.01% | 467 |
|
|
2018
Q4 | $7K | Hold |
157
| – | – | ﹤0.01% | 480 |
|
|
2018
Q3 | $12K | Hold |
157
| – | – | ﹤0.01% | 420 |
|
|
2018
Q2 | $13K | Hold |
157
| – | – | 0.01% | 389 |
|
|
2018
Q1 | $13K | Hold |
157
| – | – | ﹤0.01% | 376 |
|
|
2017
Q4 | $9K | Hold |
157
| – | – | ﹤0.01% | 415 |
|
|
2017
Q3 | $10K | Hold |
157
| – | – | ﹤0.01% | 400 |
|
|
2017
Q2 | $8K | Hold |
157
| – | – | ﹤0.01% | 424 |
|
|
2017
Q1 | $9K | Hold |
157
| – | – | ﹤0.01% | 417 |
|
|
2016
Q4 | $7K | Hold |
157
| – | – | ﹤0.01% | 454 |
|
|
2016
Q3 | $8K | Hold |
157
| – | – | ﹤0.01% | 406 |
|
|
2016
Q2 | $7K | Hold |
157
| – | – | ﹤0.01% | 417 |
|
|
2016
Q1 | $6K | Hold |
157
| – | – | ﹤0.01% | 417 |
|
|
2015
Q4 | $10K | Hold |
157
| – | – | 0.01% | 376 |
|
|
2015
Q3 | $11K | Hold |
157
| – | – | 0.01% | 363 |
|
|
2015
Q2 | $17K | Hold |
157
| – | – | 0.01% | 316 |
|
|
2015
Q1 | $15K | Buy |
+157
| New | +$17.6K | 0.01% | 327 |
|
Other funds holding AGIO
FCM
BG
AC
EAM
Valley National Advisers's AGIO Position: Q3 2024 in Review
Valley National Advisers sold out of Agios Pharmaceuticals (AGIO) in Q3 2024, closing a stake of 157 shares — an estimated $6K sold.
Valley National Advisers first reported a position in AGIO in Q1 2015 and held it in 38 quarters. The position peaked at $17K in Q2 2015. 207 funds tracked by Wall St. Rank hold AGIO as of Q3 2024.
- Valley National Advisers reported no remaining Agios Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- Valley National Advisers sold 157 Agios Pharmaceuticals shares in Q3 2024, an estimated $6K.
- Valley National Advisers first reported a position in Agios Pharmaceuticals in Q1 2015 and held it in 38 quarters.
- Valley National Advisers's Agios Pharmaceuticals position peaked at $17K in Q2 2015.
- 207 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2024.
Based on Valley National Advisers's 13F filing for Q3 2024, filed 24 Oct 2024.